284 related articles for article (PubMed ID: 26826611)
21. PACAP and its receptors in cranial arteries and mast cells.
Jansen-Olesen I; Hougaard Pedersen S
J Headache Pain; 2018 Feb; 19(1):16. PubMed ID: 29460121
[TBL] [Abstract][Full Text] [Related]
22. Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP.
Temerozo JR; Joaquim R; Regis EG; Savino W; Bou-Habib DC
PLoS One; 2013; 8(6):e67701. PubMed ID: 23818986
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Moody TW; Nuche-Berenguer B; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):38-47. PubMed ID: 26702849
[TBL] [Abstract][Full Text] [Related]
24. Multiple signal pathways coupling VIP and PACAP receptors to calcium channels in hamster submandibular ganglion neurons.
Kamaishi H; Endoh T; Suzuki T
Auton Neurosci; 2004 Mar; 111(1):15-26. PubMed ID: 15109935
[TBL] [Abstract][Full Text] [Related]
25. PAC₁ receptors mediate positive chronotropic responses to PACAP-27 and VIP in isolated mouse atria.
Hoover DB; Girard BM; Hoover JL; Parsons RL
Eur J Pharmacol; 2013 Aug; 713(1-3):25-30. PubMed ID: 23665113
[TBL] [Abstract][Full Text] [Related]
26. Pituitary adenylate cyclase activating polypeptide (PACAP) signalling exerts chondrogenesis promoting and protecting effects: implication of calcineurin as a downstream target.
Juhász T; Matta C; Katona É; Somogyi C; Takács R; Gergely P; Csernoch L; Panyi G; Tóth G; Reglődi D; Tamás A; Zákány R
PLoS One; 2014; 9(3):e91541. PubMed ID: 24643018
[TBL] [Abstract][Full Text] [Related]
27. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
29. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines.
Waschek JA; Lelievre V; Bravo DT; Nguyen T; Muller JM
Peptides; 1997; 18(6):835-41. PubMed ID: 9285932
[TBL] [Abstract][Full Text] [Related]
30. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.
Langer I; Latek D
Front Endocrinol (Lausanne); 2021; 12():711906. PubMed ID: 34867774
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
33. Calmodulin interacts with PAC1 and VPAC2 receptors and regulates PACAP-induced FOS expression in human neuroblastoma cells.
Falktoft B; Georg B; Fahrenkrug J
Neuropeptides; 2009 Apr; 43(2):53-61. PubMed ID: 19269029
[TBL] [Abstract][Full Text] [Related]
34. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Pathway Is Induced by Mechanical Load and Reduces the Activity of Hedgehog Signaling in Chondrogenic Micromass Cell Cultures.
Juhász T; Szentléleky E; Somogyi CS; Takács R; Dobrosi N; Engler M; Tamás A; Reglődi D; Zákány R
Int J Mol Sci; 2015 Jul; 16(8):17344-67. PubMed ID: 26230691
[TBL] [Abstract][Full Text] [Related]
35. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
36. Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus.
Mounien L; Bizet P; Boutelet I; Gourcerol G; Fournier A; Vaudry H; Jégou S
Neuroscience; 2006 Nov; 143(1):155-63. PubMed ID: 16962718
[TBL] [Abstract][Full Text] [Related]
37. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Timely Top Med Cardiovasc Dis; 2005 Oct; 9():E33. PubMed ID: 16341283
[TBL] [Abstract][Full Text] [Related]
38. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
39. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
40. [Pituitary adenylate cyclase-activating polypeptide].
Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
